Kornimate/medical-research-clean huggingface dataset:
viral biofilms: hijacking t cell extracellular matrix to regulate hiv-1 spread?

Conditions: HIV Infection

Summary: this project aims at characterizing hiv-1 viral biofilms structural and functional properties and at deciphering its role as a new viral reservoir and as a new mode of viral spread. the prospective national study will be conducted on cells isolated from blood samples from 20 patients infected with hiv.

the investigators' preliminary data indicate that besides " free " infectious viral particles, hiv-1 infected cluster of differentiation 4 (cd4+) lymphocytes also produce extracellular viral assemblies wrapped in an extracellular matrix cocoon and tightly bound to the surface of the cell. importantly, these structures are infectious, transferred to target cells upon intercellular contacts and they are key role in hiv-1 spread between t lymphocytes. hiv-1 viral biofilm could be important not only for direct transmission of the virions but also for " trans-infection ", a process our objectives are: * to better characterize the molecular composition and the architecture of this biofilm (using proteomics, glycomic superresolution cell imaging approaches) with regard to its properties (infectivity, adhesiveness, protection of virions) and to determine whether cells from infected patients produce such structures. * to delineate the viral factors regulating the formation of these new infectious structures (with a particular attention on tat, vpu and nef hiv-1 encoded using mutant viruses or expression vectors). * to investigate the lymphocyte pathways regulating the viral biofilms formation and composition in extracellular matrix (ecm) proteins (using quantitative polymerase chain reaction (qpcr) and sirna). * to determine whether those viral biofilms are involved in hiv-1 transmission by transinfection * to study the contribution of those infectious structures and the dynamics of their transmission in lymph nodes. this project may contribute to decipher the role of viral biofilms in hiv-1 transmission. ultimately, we intend to determine how the interference of retroviral infections with t cell activation pathways modulates the pattern of ecm production by t cells, tuning viral biofilm composition and regulating viral dissemination.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * able to give written consent * hiv positive serology hiv1 * viral load \> 10 000 copies/ml * cd4 t cells \> 100 cells/mm3 * or treated by antiretroviral therapy (arv) for less than 6 months * covered by french social security exclusion criteria: * involved in a clinical trial * pregnancy (inclusion can be postponed) * no covered by french social security

Keywords: hiv biofilm transmission
molecular characteristics of brodalumab in hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa; Acne Inversa

Summary: hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and surrounding tissues, pain, and foul-smelling discharges. effective treatment options are lacking. recently, clinical trials conducted in our lab found brodalumab was an effective drug for this disease. weekly dosing achieved superior therapeutic outcomes compared to a dosing given once in every other week. brodalumab was safe in both regimens, but blood and tissue studies to better understand this response are still needed. by performing this small pilot study and collecting blood and tissue samples from participants treated with brodalumab once weekly we would like to better characterize the molecular response to this treatment, identify blood and tissue markers reflecting disease severity, and better understand disease mechanisms.


Eligibility criteria:
inclusion criteria: * confirmed clinical diagnosis of hidradenitis suppurativa by the principal investigator * age 18 to 99 years old * moderate to severe hidradenitis suppurativa with draining tunnels (hidradenitis suppurativa severity score system/ihs4\>4) * must have medical insurance that is willing to pay for the study drug throughout the duration of the study exclusion criteria: * inflammatory bowel disease * hiv positive * active hepatitis b or c infection * pregnant or breastfeeding * no concurrent use of any systemic antibiotics/retinoids/immunosuppressants/biologics (require washout period of \>5 half-lives) * a score of \>10 on the beck's depression inventory (bdi) or on the patient health questionnaire (phq)-9 * history of keloid scarring * any medical, psychological or social condition that, in the opinion of the investigator, would jeopardize the health or well-being of the participant during any study procedures or the integrity of the data

Keywords: hidradenitis suppurativa acne inversa brodalumab
colonoscopy check-up in people with lynch syndrome

Conditions: Lynch Syndrome

Summary: lynch syndrome, an inherited condition, increases bowel cancer risk. people with lynch syndrome are recommended to have regular colonoscopies where a camera in a tube is used to look inside the bowel for cancer and for polyps (growths that sometimes can become cancerous). uk guidelines recommend that people with lynch syndrome have colonoscopy check-up every 2 years after reaching a certain age; however, they face many challenges which make it difficult to have the recommended check-up. among a subset of people with lynch syndrome in england, this study will investigate the: * percentage who are having colonoscopy check-up as recommended by uk guidelines * factors influencing whether a person is more/less likely to have the recommended colonoscopy check-up * views, experiences, and challenges of living with lynch syndrome and colonoscopy check-up this study will collect information from people in the 'lynch syndrome registry pilot' using a questionnaire. the cancer screening and prevention research group (csprg) at imperial college london are conducting the lynch syndrome registry pilot, which is recruiting people with lynch syndrome who are aged \>18 years and in the cancer prevention programme 3 (capp3) trial, from nov 2022-nov 2023. this study will include people in the lynch syndrome registry pilot who provided consent on the registry pilot consent form to be contacted about future research and are aged ≥25 years. people who have had previous surgery to remove their rectum will be excluded. the investigators will use the 'views, experiences, and challenges of colonoscopy check-up' questionnaire, together with a few pieces of additional information previously collected as part of the lynch syndrome registry pilot. participation involves completing the questionnaire only. the study will take approximately one year from administering the questionnaire to sharing results with participants.


Eligibility criteria:
inclusion criteria: * people in the lynch syndrome registry pilot who have provided consent to be contacted about future research and are aged ≥25 years exclusion criteria: * people who have had surgery involving removal of their rectum

Keywords: lynch syndrome colonoscopy surveillance
expanded access protocol of patisiran for patients with hereditary attr amyloidosis (hattr)

Conditions: TTR-mediated Amyloidosis; Amyloidosis, Hereditary; Amyloid Neuropathies, Familial; Familial Amyloid Polyneuropathies; Amyloid Neuropathies; Amyloidosis, Hereditary, Transthyretin-Related

Summary: the purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hattr).

choosing to participate in an expanded access program is an important personal decision. talk with your doctor and family members or friends about deciding to join a research study. to learn more about this study, please have your doctor contact the study research staff using the contacts provided. for general information, see the links provided in more information.

Eligibility criteria:
inclusion criteria: * male or female greater than or equal to 18 years of age * have a diagnosis of hattr * meet karnofsky performance status and polyneuropathy disability (pnd) score requirements * have adequate complete blood counts, liver function tests and coagulation tests exclusion criteria: * participated in an interventional hattr amyloidosis clinical trial involving rna interference (rnai) therapeutics within the last 12 months * are currently eligible to participate in or currently enrolled in an ongoing interventional hattr amyloidosis clinical trial * have inadequate cardiac function * known primary amyloidosis (al amyloidosis) or leptomeningeal amyloidosis * have known serious comorbidities or considered unfit for the program by the investigator * prior or planned liver or heart transplantation

Keywords: rnai therapeutic fap familial amyloid polyneuropathies ttr transthyretin amyloidosis
retinal imaging using notal-oct

Conditions: Age-Related Macular Degeneration; Diabetic Retinopathy

Summary: comparison between retinal measurements, done by the notal-oct imaging and a commercial oct (optical coherence tomography)


Eligibility criteria:
inclusion criteria: 1. ability and agreement to give informed consent (ic) 2. diagnosis of amd or dr in se by oct 3. ability to undergo oct scans 4. va of 20/160 or better in se exclusion criteria: 1. amd and dr in the same se 2. evidence of macular disease other than amd or dme in se
assessment of arresting root surface caries after the application of prg bioactive varnish

Conditions: Root Caries

Summary: guidelines proved that arresting and remineralization of the root surface caries is better than weakening the tooth structure and restoring it. manufacturer claims that prg barrier coat effectively treats dental hypersensitivity by providing immediate and long-lasting relief. also has the effect of eliminating the activity and sur-vival of pathogenic bacteria and hardening the dentin tissue of the affected areas.

a light-cured varnish with extended protection time of up to 6 months, prg barrier coat incorporates proprietary giomer tech-nology, "surface pre-reacted glass" for high fluoride release and re-charge, continuous release of fluoride, strontium, boron, sodium, aluminum, and zinc, acid neutralization and anti-plaque benefits with excellent self-adhesive abilities. the new material could be an alter-native to sdf varnish in root caries arrest to overcome its unfavor-able color and taste. products containing s-prg fillers have been developed in a wide variety of areas such as tooth surface coating materials, seal-ants, restoration resins and dentifrices. the use of these materials is also expected to have the effect of improving the properties of enamel. in this seminar, we will introduce a new caries prevention using s-prg filler the eluted ions from the s-prg filler containing materials exhibit various functions, such as prohibition of biofilm attachment, anti-demineralization, remineralization, modification of apatite crystal, and acid-buffering effect. each ion was confirmed its function. par-ticularly, strontium, borate and fluoride ions were involved during calcium phosphate nucleation to form modified nano-hydroxyapatite. the acid buffering effect was shown with the borate ion. as the results of those effects of ions, the various materials with s-prg technology were proven to con-tribute to increase the acid resistance and the caries prevention.

Eligibility criteria:
inclusion criteria: * teeth with primary root surface caries (active dentin carious le-sions) * teeth with gum recession. * teeth are vital according to pulp-sensitivity tests. * controlled gingival or periodontal conditions. exclusion criteria: * retained deciduous teeth; as the research is targeting only per-manent teeth. * teeth with previous restorations which may add another varia-ble to the study (type of old restorative material, extent of re-current caries). * spontaneous pain or prolonged pain after sensitivity tests (cold and electrical tests) indicating irreversible pulpitis. * negative sensitivity tests, periapical radiolucencies, and sensi-tivity to axial or lateral percussion indicating pulp necrosis. * teeth presenting external or internal resorption, with adverse pulpal reactions which may affect the outcome of the study.
symptom control 1-year after circular stapler anopexy or diathermy excision for prolapsed haemorhoids

Conditions: Hemorrhoids

Summary: background: in an international randomised controlled trial we studied how patient self-reported symptoms improved after either a stapled anopexy operation or a diathermy excision of the haemorrhoids. methods: the study involved 18 hospitals in sweden, denmark and the uk. two hundred and seven patients were randomised. after exclusion of 27 patients, 90 in both groups were operated and followed one year. patients provided self-reported symptoms before surgery and after 1 year. a patient diary obtained daily self-reported postoperative pain scores (vas). surgeons evaluated the anal anatomy before surgery and after 1 year.


Eligibility criteria:
inclusion criteria: * grades iii and iv haemorrhoids exclusion criteria: * previous operation for high anal fistula or injury to the anal sphincteres

Keywords: symptoms postoperative pain postoperative complications milligan anopxy
the influence of fat perception on satiety from consumption of reduced fat snacks

Conditions: Appetitive Behavior; Individual Difference; Food Sensitivity; Food Preferences

Summary: the present study aims to investigate the effect of fat level and fat type of a snack on self-reported satiety and associated biomarkers. the relevant individual differences will also be investigated.

the aims are: (1) to determine whether reducing fat in a snack leads to rebound hunger and higher food intake at the subsequent meal, (2)to determine whether a low fat snack product matched for expected satiety leads to differences in post-ingestive satiety (i.e. mouth-gut discordance), (2) to determine whether individual differences in sensory perception influence expected or post-ingestive satiety. stage 1, characterising volunteers: fat is perceived through three sensory modalities; mouthfeel, taste and odour. humans vary in their perception of fat across all sensory modalities. volunteers will be characterised on their ability to taste fatty acids and perceive mouthfeel. stage 2, establish sensory tolerance in expected satiety of a fat reduced snack model: reduced fat products are typically reformulated to match the perceived texture and mouthfeel of the original product. this stage aims to quantify sensory tolerance to fat reduction. stage 3, establish mouth gut discordance of a fat reduced snack model: using a standard preload study design, and the same fat-emulsion snack model from stage 2, the investigators will contrast effects of 3 test samples in a balanced cross-over design.

Eligibility criteria:
inclusion criteria: * men and women * aged 18-70 years * body mass index (bmi): 18-32 kg/m2 * fasting glucose \< 7 mmol/l * fasting total cholesterol \< 7.5 mmol/l * fasting triglycerides \< 2.3 mmol/l * weight stable in the last three months exclusion criteria: * diagnosed with diabetes or cardiovascular disease (e.g. stroke or heart attack), gastrointestinal (e.g. irritable bowel syndrome (ibs), inflammatory conditions, gastroenteritis), endocrine or renal diseases * smoker * taking prescribed medications that could influence study outcomes (e.g. lipid lowering medications, anti-depressants, anticoagulants) * food allergies (e.g. gluten, dairy) and intolerances (e.g. lactose) * drug abuse * anaemia (men: haemoglobin\<130 g/l and women \<115 g/l) * hypertension (systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg) * planning or currently on a weight reducing programme * pregnancy, planned pregnancy in the next year or lactating * currently taking part or participation in other research studies within the last three months

Keywords: fat oral sensitivity appetite metabolism
effect of lateral pharyngoplasty on blood pressure in obstructive sleep apnea (osa) patients

Conditions: Obstructive Sleep Apnea; High Blood Pressure

Summary: * describe blood pressure changes on patients with osa treated with lateral pharyngoplasty * compare the mean of systolic and diastolic blood pressure in 24 hours, average systolic and diastolic pressure during daytime and night and changes in the nocturnal decrease.

the variables are: ambulatory blood pressure data snoring scale bmi neck circumference abdominal circumference medications and life style changes

Eligibility criteria:
inclusion criteria: * adult patient * bmi \< 35 * no benzodiazepinec user exclusion criteria: * bmi \> 35 * use of benzodiazepinecs * clinical contra-indications to surgery (asa iii or asa iv)

Keywords: osa blood pressure lateral pharyngoplasty
study of kidney circulating cell-free dna in patients with acute kidney failure

Conditions: Kidney Failure, Acute

Summary: the amount of total circulating dna has been shown to increase in patients with acute renal failure. nevertheless, it is currently not currently possible to prove the renal origin of this circulating dna. recently, in healthy subjects, teams have shown that it is possible to identify its tissue origin of circulating dna. cgenetix is a medtech company which develops on an identical principle an in vitro diagnostic test capable of identifying and quantifying renal degradation during an acute trauma. the objective of this study is to evaluate the sensitivity of the proposed technology to detect circulating dna of renal origin released into the general circulation in patients with acute organic and functional renal failure. patients with functional or organic kidney deficiency will be included and the kidney biomarkers develop by cgenetix will be compared between these 2 groups of patients.

when the patient arrives, a first stage of checking the inclusion/non-inclusion criteria will be respected. patients who do not meet the eligibility criteria will not be sampled (pre-screening stage). patients meeting the eligibility criteria will be informed of the study by the investigator and a written information note will be given to them. if they do not object to their participation, an additional tube of blood for research purposes will be taken during a blood sample taken as soon as they are admitted as part of their usual treatment. they will also follow the standard care protocol according to the clinical recommendations of their attending physician. the objective of early sampling is to sensitize the test by assaying the marker as soon as possible after renal injury. in the event of a posteriori differential diagnosis (obstructive arf or irc), the patient will be excluded from the final analysis. patients passing the pre-screening and screening stages positively will be included in the final analysis. 90 patients should be included and divided into 2 groups: * 65 patients with non-biopsied organic acute kidney injury of which 20 patients with biopsied organic acute kidney injury (test group) * 25 patients with functional acute kidney failure (control group).

Eligibility criteria:
inclusion criteria: * age \> 18 years old * admitted for suspicion of acute renal injury (organic) and/or with an indication for renal biopsy (pbr) * patients hospitalized with functional acute renal failure (negative control and inclusion limited to n = 30 maximum) exclusion criteria: * patients \< 18 years old * patients with cognitive and mental disorders making them unable to express their non-objection to participation in the study * patients with obstructive renal failure * patients with chronic renal failure * patients who expressed their refusal to participate in the study
mesenchymal stem cells for prevention of bronchopulmonary dysplasia in infants

Conditions: Bronchopulmonary Dysplasia

Summary: the clinical study with umc119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("bpd"). this will be a dose escalation, open-label, single-center study in infants at high risk for bpd.

umc119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for prevention of bronchopulmonary dysplasia.

Eligibility criteria:
inclusion criteria: neonatal infants who fulfil all of the following criteria will be enrolled: 1. subjects of postnatal age between 3 to 30 days. 2. are male and female infants born at ga between 23 weeks to 29 weeks. the postmenstrual age of subject received umc119-01 should be no more than pma36 weeks. 3. subjects with birth weight between 501g to 1249 g. 4. have endotracheal tube in place as part of soc for preterm infants with bpd at screening and on treatment visit (day 0), and that they will have not been intubated for the purposes of this study. 5. a subject who is intubated and receiving mechanical ventilation with a fraction of inspired oxygen (fio2) of 0.25 or greater at screening. 6. a subject who has had either a deterioration or no change in the setting of mechanical ventilation within the 24 hours before trial enrollment. 7. written informed consent has been provided by the subject's parents, legal guardians, or a legal representative, who agree to comply with all of the study procedures, including those in the long-term safety surveillance period. exclusion criteria: neonatal infants who meet any of the following criteria will be excluded: 1. have a major congenital abnormality, including neurological (including anencephaly and similar malformations), hepatic, renal, cardiovascular abnormality (except for patent ductus arteriosus, pda). 2. have a known genetic syndrome. 3. have a condition that makes them ineligible for participation in this study, as determined by the investigator. 4. have c-reactive protein (crp) \>30 mg/l; or any infections including pneumonia, sepsis, or shock. 5. have pre-existing severe intraventricular hemorrhage (ivh) (grade ≥3). 6. have active pulmonary hemorrhage or air leak syndrome. 7. have abnormal hepatic (ast, alt \>150 u/l or direct bilirubin \>2 mg/dl or total bilirubin \>15 mg/dl) or renal function (serum creatinine \>1 mg/dl or oliguria). 8. are known to be infected with hiv or cmv. 9. are expected to have surgery within 24 hours prior to and/or after umc119 01 instillation. 10. are expected to receive any other intratracheal treatments, including surfactant within 72 hours prior to and/or after umc119 01 instillation. 11. are currently participating in any other interventional clinical trial.
patients treated in real life with venetoclax for waldenström macroglobulinemia

Conditions: Waldenstrom's Macroglobulinaemia Refractory

Summary: waldenström macroglobulinemia (wm) is an incurable disease. bcl2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (cll) and acute myeloid leukemia. recently, a clinical trial including 32 patients with wm treated with venetoclax showed an overall response rates of 84% and a major response rate of 81%. however, there is no in real life data, in the french population, of the efficiency of venetoclax in wm. the aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of venetoclax in wm.


Eligibility criteria:
inclusion criteria: * waldenstrom's macroglobulinemia * treatment with venetoclax * non opposition exclusion criteria: none